The Treatment of Cutaneous T-Cell Lymphoma with a Novel Retinoid

Clinical Lymphoma

Volumn 1, Issue 1 SUPPL., 2000, Pages

  Heald, Peter ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bexarotene; Erythroderma; Hypertriglyceridemia; Retinoids

Indexed keywords

ANTINEOPLASTIC AGENT; BEXAROTENE; BIOLOGICAL RESPONSE MODIFIER; TETRALIN DERIVATIVE;

CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SKIN TUMOR; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANTICARCINOGENIC AGENTS; BIOLOGICAL RESPONSE MODIFIERS; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; SKIN NEOPLASMS; TETRAHYDRONAPHTHALENES;

EID: 0345289652     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2000.s.009     Document Type: Article

References (18)

1. Smith MA, Parkinson DR, Cheson BD, et al. Retinoids in cancer therapy. J Clin Oncol 1992; 10:839-864.
2. Warrell RP Jr. Applications for retinoids in cancer therapy. Semin Hematol 1994; 31:1-13.
3. Gudas LJ. Retinoids, retinoid-responsive genes, cell differentiation, and cancer. Cell Growth Differ 1992; 3:655-662.
4. Molin L, Thomsen K, Volden G, et al. Oral retinoids in mycosis fungoides and Sezary syndrome: a comparison of isotretinoin and etretinate. A study from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol 1987; 67:232-236.
5. Thomsen K, Hammar H, Molin L, et al. Retinoids plus PUVA (RePUVA) and PUVA in mycosis fungoides, plaque stage. A report from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol 1989; 69:536-538.
6. Sinha AA, Heald P. Advances in the management of cutaneous T-cell lymphoma. Dermatol Clin 1998; 16:301-311.
7. Fuhlbrigge RC, Kieffer JD, Armerding D, et al. Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. Nature 1997; 389:978-981.
8. Heald PW, Edelson RL. Cutaneous T-cell lymphomas. In: Freedberg IM, ed. Dermatology in General Medicine. New York: McGraw Hill, 1999:1227-1249.
9. Zackheim HS, Epstein EH Jr., Crain WR.Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143 patients. J Am Acad Dermatol 1990; 22:802-810.
10. Wilson LD, Quiros PA, Kolenik SA, et al. Additional courses of total skin electron beam therapy in the treatment of patients with recurrent cutaneous T-cell lymphoma. J Am Acad Dermatol 1996; 35:69-73.
11. Herrick C, Heald P. The dynamic interplay of malignant and benign T cells in cutaneous T-cell lymphoma. Dermatol Clin 1997; 15:149-157.
12. Rook AH, Heald P. The immunopathogenesis of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995; 9:997-1010.
13. Heald P, Rook A, Perez M, et al. Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy. J Am Acad Dermatol 1992; 27:427-433.
14. Olsen EA, Rosen ST, Vollmer RT, et al. Interferon alfa-2a in the treatment of cutaneous T cell lymphoma. J Am Acad Dermatol 1989; 20:395-407.
15. Barr ML, Meiser BM, Eisen HJ, et al. Photopheresis for the prevention of rejection in cardiac transplantation. Photopheresis Transplantation Study Group. N Engl J Med 1998; 339:1744-1751.
16. Mostow EN, Neckel SL, Oberhelman L, et al. Complete remissions in psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alfa and PUVA. Arch Dermatol 1993; 129:747-752.
17. Wilson LD, Licata AL, Braverman IM, et al. Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy. Int J Radiat Oncol Biol Phys 1995; 32:987-995.
18. Duncan K, Heald P, Tallini G, et al. Utility of PCR amplification of T-cell receptor rearrangements in the definition of cutaneous T-cell lymphoma relapse. J Invest Dermatol 1998; 110:645 (Abstract).